Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic...
Vous n'êtes pas connecté
Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new therapeutic approach against GBM involves engineered dendritic cells that mimic the immune response to viral intruders. Jay Hartenbach President and Chief Operating Officer Diakonos Oncology In this Innovation Spotlight, Jay Hartenbach, the president and chief operating officer of Diakonos Oncology, explains the company’s novel dendric cell cancer vaccine DOC1021, which has shown promising results in clinical trials. By “double-loading” patient-derived immune cells with patient-specific tumor...
Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic...
CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping...
CAR T cells are patient-derived, genetically engineered immune cells. They are “living drugs” and constitute a milestone in modern medicine....
Researchers from Mass General Brigham, the Broad Institute of MIT and Harvard, USA, have identified genetic modifications that can improve the...
In a new study that combines synthetic biology with cancer immunotherapy, researchers from the Yong Loo Lin School of Medicine, National University of...
A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and...
Childhood germ cell tumors show unique immune patterns. New findings may lead to safer, smarter, and more personalized cancer treatments.
A new study, led by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine, captured details...
DUBLIN--(BUSINESS WIRE)--The "Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030" report has been...
Researchers bmeasured boron in individual live cells of medlinkhead and neck cancer/medlink, contributing to a better drug design and precision